

Form PTO-1449

Docket Number 273012012100

Application Number 10/072,215

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

H. Andrew STRONG, et al.

Filing Date February 6, 2002

Group Art Unit 1614

Mailing Date December 16, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
Z.F	1.	03/1993	5,198,460	Pandey et al.	514	410	
Z.F	2.	08/1998	5,798,349	Levy et al.	514	185	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
Z.F	3.	08/2002	WO 02/062384	WIPO			
Z.F	4.	08/2002	WO 02/062386	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
Z.F	5.	Michels, S. et al., "Changes in Neovascular Membranes and Normal Choroid Blood Vessels After Multiple Photodynamic Therapy Treatments!" Ophthalmologie 99(2):96-100 (2002)
Z.F	6.	Schmidt-Erfurth, U. et al., "Photodynamic Therapy with Verteporfin for Choroidal Neovascularization Caused by Age-Related Macular Degeneration: Results of Retreatment in a Phase 1 and 2 Study" Archives of Ophthalmology 117(9):1177-1187 (1999)
Z.F	7.	Sickenberg, M. et al., "A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia Ocular Histoplasmosis Syndrome, Angioid Streaks, and Idiopathic Causes" Archives of Ophthalmology 118(3):327-336 (2000)
Z.F	8.	Scott, L. et al., "Verteporfin." Drugs & Aging 16(2):139-148 (2000)
Z.F	9.	Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. "Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin" Arch. Ophthalmol. 117: 1329-1345 (1999)

RECEIVED

JAN 02 2003
TECH CENTER 1600/2900

EXAMINER:

Zahid Fay

DATE CONSIDERED:

6/5/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.